DelveInsight's Airway Clearance Devices for Cystic Fibrosis Market Insights report provides the current and forecast market ...

By the time Enid Katz was two years old, she had already suffered through several bouts of bronchitis and was always hungry, ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

[72] The ideal biomarker for gene therapy trials would change quickly ... proof-of-principle for gene transfer into the cystic fibrosis (CF) lung. It is currently unknown whether gene transfer ...

Allison John and Rocky When Allison John was 13 and watching the science programme Tomorrow’s World , a segment on gene therapy came up. This was cutting edge stuff in the early 1990s and John had ...

Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...

CRISPR & Cas Genes Market Growing funding in gene therapy worldwide is a prominent factor driving the CRISPR & Cas genes market.

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...